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Abstract
Background The number of older patients with cancer is increasing in general, and ovarian and endometrial cancer are to a 
large extent cancers of the elderly. Older patients with cancer have a high prevalence of comorbidity. Comorbidity and age 
may be predictive of treatment choice and mortality in older patients with cancer along with stage and performance status.
Objectives The aim of this study was to describe comorbidity in a population of older Danish patients with gynecological 
cancer, and to evaluate the predictive value of comorbidity and age on treatment choice and cancer-specific and all-cause 
mortality.
Materials and methods In this retrospective study, we included 459 patients aged ≥ 70 years. Patients were diagnosed with 
cervical, endometrial, or ovarian cancer from 1 January, 2007 to 31 December, 2011 and were evaluated and/or treated at 
Odense University Hospital. Comorbidity was assessed using the Charlson Comorbidity Index. Treatment was classified as 
curative intended, palliative intended, or no treatment.
Results Age, International Federation of Gynecology and Obstetrics (FIGO) stage, and performance status were found to 
be significant predictors of treatment choice, while comorbidity was not. Multivariate analyses showed that both cancer-
specific and all-cause mortality were significantly associated with treatment choice, FIGO stage, and performance status. Age 
was not associated with mortality, with the exception of ovarian cancer, where age was associated with all-cause mortality. 
Comorbidity was not an independent predictor of treatment choice or mortality.
Conclusions In our population of older Danish patients with gynecological cancer, age, FIGO stage, and performance status 
were predictors of treatment choice, while comorbidity was not. Treatment choice, FIGO stage, and performance status were 
significantly associated with both cancer-specific and all-cause mortality. Age was only associated with mortality in ovarian 
cancer, while comorbidity was not associated with mortality.
Key Points 
Significant predictors of treatment choice in older 
patients with gynecological cancer include age, Interna-
tional Federation of Gynecology and Obstetrics (FIGO) 
stage, and performance status, but not comorbidity
Significant predictors of both cancer-specific and all-
cause mortality in older patients with gynecological 
cancer were treatment choice, FIGO stage, and perfor-
mance status
Age was only a significant predictor of mortality in 
patients with ovarian cancer
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1 Introduction
The number of older patients with cancer is increasing 
as a result of the aging population. Today, almost half of 
all cancer survivors (47%) in USA are aged 70 years or 
older [1]. Gynecological cancers include malignancies of 
the uterine cervix, endometrium, ovaries, fallopian tubes, 
peritoneum, vagina, and vulva. A recent study, examining 
trends in gynecological cancers in older women, found 
that women aged 70 years and above with cervical, endo-
metrial, or ovarian cancer had a two to three times higher 
mortality rate compared with women aged < 70 years. 
This was the case despite different characteristics regard-
ing etiology, incidence, stage at diagnosis, and treatment 
options [2].
Comorbidity is defined as the presence of additional 
diseases in relation to an index disease in one individual 
[3]. Older patients with cancer have a higher number of 
comorbidities than younger patients, and the likelihood 
of co-existing conditions increases with age. Depending 
on the number and severity of comorbid conditions, these 
might have an impact on patients’ health status and their 
treatment. In addition to comorbidity itself, age has been 
shown to be a significant predictor of comorbid death 
[4]. Comorbidity has an impact on the toxicity of a given 
treatment in older patients with cancer [5] and therefore 
might influence the treatment offered. An earlier study 
found that age ≥ 70 years as well as severe comorbidity, 
expressed by a score of ≥ 3 in the American Society of 
Anesthesiologists (ASA) physical status classification sys-
tem, were independent predictors for not undergoing sur-
gery or receiving standard combination chemotherapy in 
patients with ovarian cancer [6]. The aim of this study was 
to describe comorbidity in a population of older patients 
with gynecological cancer, and to evaluate the predictive 
value of comorbidity and age on treatment choice and 
cancer-specific and all-cause mortality.
2  Materials and Methods
This is a retrospective register-based cohort study. The 
study population consists of women aged 70 years or more, 
diagnosed with gynecological cancer from 1 January, 2007 
to 31 December, 2011 at the Department of Gynecology 
and Obstetrics at Odense University Hospital located in 
Southern Denmark. The patients were evaluated and/or 
treated for their malignant disease in this department and/
or in the Department of Oncology at the same center. The 
center treats residents of Funen, which comprises 9% 
of the Danish population in addition to the majority of 
Southern Jutland, and a previous validation study has con-
cluded that the population of Funen is representative of the 
entire Danish population [7]. The diagnoses included were 
cervical cancer [International Classification of Diseases, 
10th Revision (ICD-10)] (code C53), endometrial cancer 
(codes C54–55), ovarian cancer (code C56), fallopian tube 
cancer (code C57), and primary peritoneal cancer (code 
C48). Cancers of the ovaries, fallopian tubes, and perito-
neum were considered as one entity and will be referred 
to as “ovarian cancer” in this article. Only patients with 
epithelial ovarian cancers were included and patients with 
borderline tumors were excluded.
2.1  Data Sources
All Danish citizens have been assigned a personal identifica-
tion number since 1968. This enables linkage of data from 
different registers and databases [8]. Eligible patients were 
identified in The Danish Gynecological Cancer Database 
(DGCD). All pathology results of the patients were reviewed 
to confirm diagnoses. Supplementary data were obtained 
from the Danish Causes of Death Register and the National 
Patient Register (NPR), in addition to the medical charts of 
the patients.
The DGCD is a nationwide multidisciplinary clinical 
database. It contains disease-specific information on women 
diagnosed with gynecological cancer from 1 January, 2005 
and onward. There are three categories of data available; 
surgical, pathological, and oncological. Variables available 
in the DGCD include date of diagnosis, performance status 
(PS), date and extent of surgery, stage, histological type and 
grading, residual disease, and intended treatment. A valida-
tion study found that data on surgery and pathology were 
valid for research [9]. Data on oncological treatment were 
incomplete and have been omitted since July 2013.
Information regarding all deaths in Denmark is collected 
in the Danish Causes of Death Register [10]. The infor-
mation originates from death certificates, the completion 
of which became mandatory in 1871. It includes date and 
cause of death ranging from the main to the contributory and 
immediate causes for each individual. Causes of death are 
coded according to the ICD-10.
Where relevant data were not obtainable from the 
above-mentioned databases and registers, the medical 
charts of patients were reviewed. In particular, oncologi-
cal data were supplemented from medical charts. Staging 
of the cancers was based on the International Federation 
of Gynecology and Obstetrics (FIGO) staging pooled into 
three groups: (1) FIGO stage I: localized tumors and (2) 
FIGO stage II and III: tumors with regional metastases and 
FIGO stage IV: tumors with distant metastases. Informa-
tion regarding stage was obtained from the DGCD with 
supplementation from medical charts. Age at diagnosis 
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was divided into four age groups: (1) 70–74 years; (2) 
75–79 years; (3) 80–84 years; and (4) ≥ 85 years.
The Charlson Comorbidity Index (CCI) is a weighted 
comorbidity index including 19 chronic conditions. The 
CCI has been validated in a population of patients with 
cancer [4, 11]. In our study, we included non-malignant 
comorbidity, and the CCI score was grouped into three 
categories: (1) no comorbidity: CCI score 0; (2) mild-
to-moderate comorbidity: CCI score 1–2; and (3) severe 
comorbidity: CCI score ≥ 3. This grouping has been used 
in previous studies [12]. The CCI score was constructed 
from diagnoses in the NPR treated at Danish hospitals. 
The NPR was established in 1977 [13]. All inpatient and 
outpatient contacts are registered with an ICD-10 diagno-
sis code. Adaption of the CCI for use with ICD administra-
tive data has been validated in older patients with cancer 
[14].
Permission was obtained from the Danish Health Author-
ity (Journal no. 3-3013-1078/1/). The end of follow-up was 
June 2017 for date of death. Causes of death were available 
up to 31 December, 2015.
2.2  Definition of Intended Treatment Groups
All patients were divided into three groups based on the 
intended treatment: curative, palliative, or none. Below is a 
summary of the antineoplastic therapies used in the period 
2007–2011 at the department.
Ovarian cancer: Curative intended treatment included 
primary surgery followed by postoperative chemotherapy 
or neoadjuvant chemotherapy followed by interval debulking 
surgery (if possible) and then additional postoperative chem-
otherapy. Chemotherapy included carboplatin and paclitaxel 
or carboplatin as a single agent. Palliative treatment con-
sisted of chemotherapy only. Endometrial cancer: Cura-
tive intended treatment included surgery in the majority of 
patients. According to risk factors, adjuvant or supplemen-
tal radiotherapy or medical oncological treatment, primar-
ily carboplatin and paclitaxel, was administered. Palliative 
treatment consisted of systemic treatment or radiotherapy. 
Cervical cancer: Curative intended therapy included surgery 
(stage IA–IIA), followed by radiotherapy in the case of high-
risk or residual disease, or primary chemo-radiotherapy. This 
consisted of external beam radiation with weekly concomi-
tant cisplatin (chemo-radiation), and vaginal brachytherapy 
(in patients who did not undergo surgery). Stage IIB and 
higher received curative chemo-radiation or palliative treat-
ment. Palliative treatment consisted of systemic treatment, 
and in rare cases, radiotherapy. No treatment was defined 
as the absence of any surgical or oncological treatment and 
included patients who refused treatment or were too frail to 
receive any disease-oriented therapy.
2.3  Statistical Analysis
The Fisher’s exact test was used to investigate a possible 
association between comorbidity and treatment choice, 
and between FIGO stage and treatment choice. The non-
parametric K sample test for equality of medians was used 
to investigate if there was an association between age and 
treatment choice. Ordered logistic regression was used to 
examine if comorbidity, FIGO stage, and age were associ-
ated with treatment choice. We estimated variance inflation 
factors to investigate possible collinearity between explana-
tory variables. A variance inflation factor > 10.0 indicated 
collinearity. The Kaplan–Meier method was used to estimate 
all-cause mortality, calculating the time from the date of 
diagnosis until death, regardless of the cause of death, or end 
of the follow-up. The Log rank test was used to investigate 
whether there was a difference in survival according to the 
treatment planned. A multivariate competing risk analysis 
was performed to estimate sub-hazard ratios for the adjusted 
association between CCI groups and cancer-specific mortal-
ity, adjusting for FIGO stage, age, treatment choice, diagno-
sis, and PS. The covariates were selected based on clinical 
meaningfulness. The Cox proportional hazards regression 
model was used to assess the adjusted association between 
the CCI group (with a CCI score of 0 as the reference) and 
all-cause mortality from the date of diagnosis, adjusting for 
FIGO stage, age, treatment choice, diagnosis, and PS. The 
proportional hazards assumption was tested using Schoe-
nfeld residuals, and the model was found fit for use. All 
statistical analyses were performed with STATA Version 15 
(StataCorp LP, College Station, TX, USA). A result was 
considered statistically significant at p values < 0.05. The 
study was approved by the Danish Data Protection Agency 
(Journal no. 15/19896).
3  Results
A total of 459 patients were included, of whom 186 had 
ovarian cancer, 219 had endometrial cancer, and 54 had cer-
vical cancer (Table 1). Two hundred and ninety-six patients 
(64.5%) received curative intended treatment, 121 patients 
(26.4%) received palliative treatment, while 42 patients 
(9.2%) did not receive any treatment at all.
3.1  Comorbidity
A total of 188 (41%) of the patients had at least one comor-
bidity. Overall, the three most common comorbidities were 
cerebrovascular disease (9.6%), chronic pulmonary disease 
(8.7%), and peripheral vascular disease (7.8%). These were 
also the three most common comorbidities in the pallia-
tive intended treatment and the no treatment groups. In the 
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curative intended treatment group, the second most common 
comorbidity after cerebrovascular disease (9.5%) was non-
complicated diabetes mellitus (8.8%). These patients also 
had a high prevalence of complicated diabetes mellitus. No 
significant association was found between comorbidity and 
treatment choice (Table 2).
3.2  Stage
The FIGO stage was available for 400 patients, and it was 
associated with choice of treatment (Table 3). Of the 59 
patients with a missing stage, 55 had endometrial cancer. 
The difference in stages among treatment groups was stati-
cally significant (p < 0.05).
3.3  Age
In the curative intended treatment group, median age 
(range) was 76 (72–80) years, while it was 78 (74–81) 
years and 81 (76–86) years for the palliative and no treat-
ment groups, respectively. The difference in age between 
treatment groups was statistically significant both overall 
(p = 0.000) and within each diagnosis (ovarian cancer: 
p = 0.000, endometrial cancer: p = 0.002, and cervical 
Table 1  Patient characteristics
CCI Charlson Comorbidity Index, FIGO International Federation of 
Gynecology and Obstetrics, IQR interquartile range
Cancer type Ovarian Endometrial Cervical
Total, n 186 219 54
Age, median (IQR), years 76 (72–80) 76 (73–81) 78 (74–83)
FIGO stage, n (%)
 I 30 (16.1) 102 (46.6) 12 (22.2)
 II–III 111 (59.7) 52 (23.7) 30 (55.6)
 IV 43 (23.1) 10 (4.6) 10 (18.5)
 Unknown 2 (1.1) 55 (25.1) 2 (3.7)
Intended treatment, n (%)
 Curative 79 (42.5) 188 (85.8) 29 (53.7)
 Palliative 84 (45.2) 20 (9.1) 17 (31.5)
 No treatment 23 (12.4) 11 (5.0) 8 (14.8)
Comorbidity, n (%)
 CCI 0 114 (61.3) 124 (56.6) 33 (61.1)
 CCI 1–2 62 (33.3) 76 (34.7) 16 (29.6)
 CCI 3+ 10 (5.4) 19 (8.7) 5 (9.3)
Performance status, n (%)
 0 66 (35.5) 84 (38.4) 20 (37.0)
 1 66 (35.5) 63 (28.8) 8 (14.8)
 2 33 (17.8) 28 (12.8) 8 (14.8)
 3 8 (4.3) 8 (3.7) 4 (7.4)
 4 3 (1.6) 3 (1.4) 1 (1.9)
 Unknown 10 (5.4) 33 (15.1) 13 (24.1)
Table 2  Distribution of diagnoses and Charlson Comorbidity Index 
(CCI) scores according to treatment choice groups
CCI score Curative 
treatment N 
(%)
Palliative 
treatment N 
(%)
No treatment N 
(%)
P value
Ovarian cancer
 0 47 (59.5) 53 (63.1) 14 (61.0)
 1–2 26 (32.9) 28 (33.3) 8 (34.8)
 ≥ 3 6 (7.6) 3 (3.6) 1 (4.3) 0.884
Endometrial cancer
 0 103 (54.8) 14 (70.0) 7 (63.6)
 1–2 69 (36.7) 4 (20.0) 3 (27.3)
 ≥ 3 16 (8.5) 2 (10.0) 1 (9.1) 0.566
Cervical cancer
 0 16 (55.2) 12 (70.6) 5 (62.5)
 1–2 10 (34.5) 4 (23.5) 2 (25.0)
 ≥ 3 3 (10.3) 1 (5.9) 1 (12.5) 0.865
All cancer sites
 0 166 (56.1) 79 (65.3) 26 (61.9)
 1–2 105 (35.5) 36 (29.8) 13 (31.0)
 ≥ 3 25 (8.5) 6 (5.0) 3 (7.1) 0.474
Table 3  Distribution of diagnoses and International Federation of 
Gynecology and Obstetrics stages according to treatment choice 
groups
Bolded values represent statistically significant results
Stage Curative 
treatment N 
(%)
Palliative 
treatment N 
(%)
No treatment N 
(%)
P value
Ovarian cancer
 I 28 (35.4) 0 (0.0) 2 (8.7)
 II–III 43 (54.4) 57 (67.9) 11 (47.8)
 IV 8 (10.1) 25 (29.8) 10 (43.5)
 Unknown 0 (0.0) 2 (2.4) 0 (0.0) 0.000
Endometrial cancer
 I 98 (52.1) 4 (20.0) 0 (0.0)
 II–III 47 (25.0) 5 (25.0) 0 (0.0)
 IV 3 (1.6) 4 (20.0) 3 (27.3)
 Unknown 40 (21.3) 7 (35.0) 8 (72.7) 0.000
Cervical cancer
 I 11 (37.9) 0 (0.0) 1 (12.5)
 II–III 16 (55.2) 10 (58.8) 4 (50.0)
 IV 2 (6.9) 6 (35.3) 2 (25.0)
 Unknown 0 (0.0) 1 (5.9) 1 (12.5) 0.006
All cancer sites
 I 137 (46.3) 4 (3.3) 3 (7.1)
 II–III 106 (35.8) 72 (59.5) 15 (35.7)
 IV 13 (4.4) 35 (28.9) 15 (35.7)
 Unknown 40 (13.5) 10 (8.3) 9 (21.4) 0.000
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cancer: p = 0.001). When adjusting for comorbidity, stage, 
and PS, the association between age and treatment choice 
still persisted and was significant. This association was 
mainly seen in patients with ovarian cancer (Table 4). 
In summary, patients with higher age were less likely to 
receive more aggressive treatment.
3.4  Treatment Choice
Ordered logistic regression with curative treatment as 
a dependent variable and adjustment for comorbidity, 
FIGO stage, age, diagnosis, and PS showed that FIGO 
stage, age, and PS were significant predictors of treatment 
choice both when the diagnoses were pooled and when 
analyzed separately (Table 4). Thus, both higher FIGO 
stage and higher age resulted in less aggressive treatment. 
Comorbidity did not influence treatment choice after 
adjustment for the above-mentioned factors (Table 4).
3.5  Cancer‑Specific and All‑Cause Mortality
At the end of the follow-up, 171 patients were still alive, 
while 288 had died. Date of death could not be obtained 
for four patients, who were excluded from further analysis 
regarding survival. Cause of death was available for 278 
patients. Cause of death was missing for six patients, who 
were excluded from the cancer-specific survival analysis.
Patients with ovarian cancer who received curative 
intended treatment had a median survival of 3.7 years [95% 
confidence interval (CI) 2.7–not reached], while those who 
received palliative treatment had a median survival of 1.3 
years (95% CI 0.2–1.7). Those who received no treatment 
had a median survival time of 0.2 years (95% CI 0.1–0.4). 
None of the patients with endometrial cancer who received 
curative intended treatment had died at the time of the fol-
low-up, while those who received palliative treatment had a 
median survival time of 0.5 years (95% CI 0.3–2.1). Those 
who received no treatment had a median survival time of 
0.2 years (95% CI 0.1–0.6). Patients with cervical cancer 
Table 4  Ordered logistic regression with curative treatment as the dependent variable and adjustment for all listed variables
Bolded values represent statistically significant results
Note: Variance inflation factor for performance status = 1.20 and variance inflation factor for FIGO stage = 1.11
CCI Charlson Comorbidity Index, CI confidence interval, FIGO International Federation of Gynecology and Obstetrics, HR hazard ratio, Ref. 
reference
Overall, n = 459
Adjusted HR (95% CI)
Ovarian cancer, n = 186
Adjusted HR (95% CI)
Endometrial cancer, n = 219
Adjusted HR (95% CI)
Cervical cancer, n = 54
Adjusted HR (95% CI)
Comorbidity
 CCI 0 Ref. Ref. Ref. Ref.
 CCI 1–2 0.8 (0.4–1.4) 1.1 (0.5–2.3) 0.6 (0.1–2.9) 0.3 (0.0–2.4)
 CCI 3+ 0.5 (0.2–1.6) 0.5 (0.1–2.2) 0.7 (0.1–9.0) 1.2 (0.1–11.4)
FIGO stage
 I Ref. Ref. Ref. Ref.
 II–III 12.6 (4.6–34.2) 94.6 (13.9–641.8) 1.6 (0.3–8.0) 4.4 (0.4–53.8)
 IV 44.9 (14.4-140.1) 210.2 (26.8–1647.6) 59.8 (6.2–577.8) 18.3 (1.2–288.7)
Age, years
 70–74 Ref. Ref. Ref. Ref.
 75–79 2.5 (1.3–4.9) 2.7 (1.2–5.8) 4.6 (0.6–35.6) 0.9 (0.1–10.1)
 80–84 4.1 (1.8–9.3) 6.4 (2.1–19.5) 3.1 (0.3–26.1) 7.5 (0.8–71.4)
 ≥ 85 12.9 (4.8–35.2) 23.6 (4.7–118.9) 10.8 (1.1–110.5) 6.5 (0.5–89.2)
Diagnosis
 Ovarian cancer Ref. Ref. Ref. Ref.
 Endometrial cancer 0.1 (0.0–0.2) – – –
 Cervical cancer 0.6 (0.3–1.4) – – –
Performance status
 0 Ref. Ref. Ref. Ref.
 1 1.3 (0.7–2.5) 1.5 (0.7–3.3) 1.7 (0.3–10.5) 1.7 (0.2–3.3)
 2 3.1 (1.4–6.6) 4.2 (1.5–11.4) 3.5 (0.5–24.8) 5.3 (0.5–54.9)
 3 13.8 (3.6–53.7) 108.3 (9.6–1219.4) 4.3 (0.3–73.0) 23.7 (0.9–642.6)
 4 25.0 (2.3–274.8) 41.2 (3.1–556.0) – –
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who received curative treatment had a median survival 
time of 6.3 years (95% CI 3.2–not reached), while those 
who received palliative treatment had a median survival 
time of 1.5 years (95% CI 0.7–2.5). Those who received no 
treatment had a median survival time of 0.4 years (95% CI 
0.01–3.4).
Multivariate analysis (pooling all three diagnoses) 
showed that both cancer-specific and all-cause mortality 
were significantly associated with treatment choice and 
FIGO stage (Tables 5 and 6). Age and comorbidity were not 
associated with mortality.
For patients with ovarian cancer, treatment choice and 
FIGO stage were significantly associated with both can-
cer specific and all-cause mortality. In addition, age was 
significantly associated with all-cause mortality, whereas 
comorbidity did not significantly influence mortality 
(Tables 5 and 6). For patients with endometrial cancer, 
no significant association was found between any of the 
adjustment factors (comorbidity, age, stage, treatment 
choice, and PS) and cancer-specific mortality. All-cause 
mortality was significantly associated with stage and treat-
ment choice (Tables 5 and 6). For patients with cervical 
cancer, all-cause mortality was significantly associated 
with no treatment. The analysis regarding cancer-specific 
mortality could not be performed for patients with cervical 
cancer alone because of the low number of patients with 
this diagnosis (Tables 5 and 6).
Table 5  Cancer-specific 
mortality
Bolded values represent statistically significant results
Note: Competing risk analysis with adjustment for all listed variables. Analysis was not possible for cervi-
cal cancer because of a low number of patients
CCI Charlson Comorbidity Index, CI confidence interval, FIGO International Federation of Gynecology 
and Obstetrics, SHR sub-hazard ratio, Ref. reference
Overall, n = 459
Adjusted SHR (95% CI)
Ovarian cancer, n = 186
Adjusted SHR (95% CI)
Endome-
trial cancer, 
n = 219
Adjusted SHR 
(95% CI)
Comorbidity
 CCI 0 Ref. Ref. Ref.
 CCI 1–2 1.2 (0.8–1.6) 1.1 (0.7–1.6) 1.2 (0.5–2.9)
 CCI 3+ 1.1 (0.4–2.5) 0.7 (0.2–2.4) 1.8 (0.4–8.1)
FIGO stage
 I Ref. Ref. Ref.
 II–III 2.7 (1.4–5.0) 3.1 (1.2–8.5) 1.8 (0.7–4.8)
 IV 4.2 (2.0–8.6) 4.7 (1.7–13.3) 4.6 (0.7–31.7)
Age, years
 70–74 Ref. Ref. Ref.
 75–79 1.3 (0.9–2.0) 1.3 (0.8–1.9) 1.7 (0.6–4.9)
 80–84 1.5 (0.9–2.6) 2.0 (1.0–3.9) 1.4 (0.5–4.0)
 ≥ 85 1.3 (0.6–2.9) 0.5 (0.1–2.1) 2.0 (0.5–7.8)
Treatment choice
 Curative treatment Ref. Ref. Ref.
 Palliative treatment 2.1 (1.4–3.2) 2.1 (1.3–3.3) 1.8 (0.5–6.2)
 No treatment 5.1 (2.4–10.9) 10.2 (4.2–24.8) 1.3 (0.1–22.2)
Diagnosis
 Ovarian cancer Ref. – –
 Endometrial cancer 0.5 (0.3–0.8) – –
 Cervical cancer 0.3 (0.1–0.6) – –
Performance status
 0 Ref. Ref. Ref.
 1 1.1 (0.7–1.5) 1.0 (0.7–1.5) 0.5 (0.2–1.5)
 2 1.0 (0.5–1.7) 0.7 (0.4–1.3) 1.5 (0.4–5.9)
 3 0.5 (0.2–1.8) 0.2 (0.0–1.5) 2.3 (0.4–13.5)
 4 9.3 (2.8–31.0) 6.6 (2.5–17.3) –
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4  Discussion
Comorbid conditions are common in older patients with 
cancer, and these patients have a higher prevalence of 
comorbidity than age-matched controls without cancer 
[12]. In addition, it has been shown that the existence of 
comorbidity in patients with cancer influences prognosis, 
treatment choice, and overall survival [14].
The prevalence of comorbidity in our population was 
41.0%, which is in line with earlier findings in an older 
population with various cancer diagnoses [15]. Age, FIGO 
stage, and PS were significant predictors of treatment 
choice, while comorbidity assessed as CCI was not. FIGO 
stage, PS, and treatment choice were significant predictors 
of both cancer-specific and all-cause mortality (for ovarian 
cancer, age was also a significant predictor of all-cause 
mortality), but comorbidity was not a significant predictor 
for mortality.
A previous Danish study including 1540 patients with 
ovarian cancer diagnosed between 2000 and 2011 found that 
68% had a CCI score of 0, 23% had a score of 1–2, while the 
remaining 8% had a score of ≥ 3 [16]. This is comparable to 
our ovarian cancer population, although a CCI score of 1–2 
was found in 33.3%. The same study found an increasing 
prevalence of comorbidity with increasing age during the 
study period, but with only little change in survival. They 
credit the centralization and more extensive surgery that has 
occurred in the same period as factors that have counteracted 
the decrease in survival that would have been expected [16].
The influence of comorbidity on survival in ovarian 
cancer is diverging, as some studies have reported that 
comorbidity impacts survival in this population [17–24], 
Table 6  All-cause mortality
Bolded values represent statistically significant results
Note: Cox proportional hazards model with adjustment for all listed variables
CCI Charlson Comorbidity Index, CI confidence interval, FIGO International Federation of Gynecology and Obstetrics, HR hazard ratio, Ref. 
reference
Overall, n = 459
Adjusted HR (95% CI)
Ovarian cancer, n = 186
Adjusted HR (95% CI)
Endometrial cancer, n = 219
Adjusted HR (95% CI)
Cervical cancer, n = 54
Adjusted HR (95% CI)
Comorbidity
 CCI 0 Ref. Ref. Ref. Ref.
 CCI 1–2 1.0 (0.8–1.4) 0.9 (0.6–1.3) 1.2 (0.7–2.1) 2.1 (0.6–7.4)
 CCI 3+ 1.3 (0.7–2.2) 1.0 (0.4–2.2) 1.7 (0.6–5.2) 1.7 (0.4–7.5)
FIGO stage
 I Ref. Ref. Ref. Ref.
 II–III 2.5 (1.6–3.7) 2.5 (1.3–5.0) 3.0 (1.6–5.6)
 IV 3.9 (2.4–6.5) 4.1 (1.9–8.8) 6.2 (1.9–20.0)
Age, years
 70–74 Ref. Ref. Ref. Ref.
 75–79 1.2 (0.9–1.7) 1.2 (0.8–1.7) 1.7 (0.9–3.4) 1.6 (0.4–6.7)
 80–84 1.3 (0.8–2.0) 2.0 (1.1–3.4) 0.6 (0.2–1.4) 0.8 (0.2–3.9)
 ≥ 85 1.6 (0.9–2.7) 2.8 (1.2–6.4) 1.1 (0.4–2.8) 0.6 (0.1–3.4)
Treatment choice
 Curative treatment Ref. Ref. Ref. Ref.
 Palliative treatment 2.7 (1.8–4.0) 2.1 (1.3–3.3) 12.9 (5.4–30.8) 3.0 (0.7–12.9)
 No treatment 8.8 (4.9–15.8) 7.7 (3.2–18.1) 71.2 (7.9–643.8) 4.7 (2.1–56.7)
Diagnosis
 Ovarian cancer Ref. – – –
 Endometrial cancer 0.8 (0.6–1.3) – – –
 Cervical cancer 0.6 (0.3–0.9) – – –
Performance status
 0 Ref. Ref. Ref. Ref.
 1 1.2 (0.9–1.7) 1.2 (0.8–1.8) 1.4 (0.7–2.7) 1.6 (0.4–6.2)
 2 1.5 (1.0–2.2) 1.0 (0.6–1.8) 3.2 (1.4–7.4) 2.3 (0.5–10.4)
 3 1.9 (0.9–3.7) 1.6 (0.5–4.9) 3.2 (0.8–13.2) 1.9 (0.2–16.7)
 4 9.4 (3.2–27.6) 8.0 (2.3–28.6) – –
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while other studies, like ours, do not find this association 
[25–27]. Sperling et al. [17] found that PS mediates some 
of the impact of comorbidity on survival, as the hazard ratio 
decreased from 1.31 to 1.17, when including PS, and that 
comorbidity had a lesser impact on survival compared with 
other factors such as stage, PS, and residual tumor status. A 
meta-analysis exploring comorbidity and survival in patients 
with ovarian cancer, based on a limited number of studies 
including the one described above, found a hazard ratio of 
1.20 (95% CI 1.11–1.30) for presence vs. absence of comor-
bidity [28]. The results of the study should be interpreted 
with caution, as it was not possible to control for potential 
confounders that were not included in the original studies. 
The studies were adjusted for different potential confound-
ers, and the possibility of unmeasured or residual confound-
ing could not be excluded [28].
Only a limited number of studies have been performed 
examining the association between comorbidity and treat-
ment choice. Sperling et al. [17] did not find an associa-
tion between comorbidity and surgical treatment choice. 
The authors interpreted their results of the lesser impact of 
comorbidity on survival as an indication that a treatment 
decision is primarily based on stage and PS. These results 
are in line with our finding that comorbidity did not impact 
treatment choice as much as age and FIGO stage. Noer et al. 
[29] also did not find an association between comorbidity 
and treatment choice, when adjusting for age and FIGO 
stage, in a population of 5317 patients with ovarian cancer. 
Another study has indicated that comorbidity may have a 
lesser impact on surgical treatment decisions than on chemo-
therapeutic treatment decisions for some cancers, but this 
has not been studied in gynecological cancer so far [30].
In a population of patients with stage I endometrial can-
cer aged ≥ 60 years, comorbidity did not influence surgery 
rate, but two or more comorbidities reduced the likelihood 
of receiving adjuvant radiotherapy (0.6, 95% CI 0.3–1.0) 
[31]. The same study found poorer survival in patients with 
comorbidity, especially those with comorbidities already 
associated with endometrial cancer that are related to obesity 
such as diabetes mellitus and cardiovascular disease [31].
We expected that an increased prevalence of comor-
bidity was associated with less aggressive treatment. A 
difference in comorbidity between the treatment choice 
groups might have been found using a different comor-
bidity index. An earlier study from our group in women 
with ovarian cancer showed that both age (≥ 70 years) 
and severe comorbidity assessed by the ASA classifica-
tion (ASA score ≥3) was independently predictive of not 
undergoing surgery or receiving standard combination 
chemotherapy (carboplatin and paclitaxel) [6]. In this con-
text, it should be noted that the tendency was that younger 
patients with ovarian cancer received monotherapy only 
in cases of a poor PS, while carboplatin monotherapy is 
frequently chosen in older patients because of high age 
alone [6]. The ASA classification is strongly based on 
functional status such as PS, which may explain its pre-
dictive value in this study.
A previous study conducted in 11,139 patients with ovar-
ian cancer showed that the impact of comorbidity was most 
pronounced in subgroups, where the overall cancer mortal-
ity is lower, such as patients with less aggressive cancer 
and younger patients [32]. Read et al. [33] also came to the 
conclusion that comorbidities had the greatest impact among 
groups with higher survival rates in a population of patients 
with various cancer diagnoses. This may also partly explain 
the findings from our older cancer population.
Different comorbidities may also affect outcomes differ-
ently, as in the case of the study of patients with endometrial 
cancer referred to earlier [31]. We found a relatively high 
prevalence of both mild-to-moderate and severe comor-
bidity in the curative treatment choice group. It is possible 
that patients with comorbid conditions might have a better 
chance of early detection of their malignant disease, simply 
because of their increased contact with physicians and hospi-
tals and a resulting increase in examinations. This hypothesis 
is supported by a study, which found that comorbidity bur-
den was associated with higher rates of mammography and 
an earlier stage at diagnosis in patients with breast cancer 
[34]. Although it has been argued that comorbidity can mask 
early cancer symptoms, most studies have found a higher 
prevalence of comorbidity in patients with early-stage can-
cer. This association seems, however, to be dependent on the 
specific comorbid condition [35]. As mentioned earlier, the 
lack of associations between the CCI and cancer-specific and 
all-cause mortality could be owing to the treatment choice 
primarily being based on the oncologist’s assessment of 
PS and FIGO. It is also possible that comorbidities were 
managed well enough not to influence mortality in this 
population.
As the NPR only includes information about contacts/
discharges from non-psychiatric hospitals, emergency 
rooms, and outpatient visits, it is possible that milder cases 
of certain conditions such as diabetes mellitus and chronic 
pulmonary disease are underreported in this study, as these 
are usually treated by general practitioners in Denmark. A 
previous study has, however, found the accuracy of NPR 
coding of CCI comorbidities consistently high [36]. As pro-
posed in the meta-analysis by Jiao et al. [28], underreporting 
of comorbidity would bias the association between comor-
bidity and survival toward the null value. We only assessed 
non-malignant comorbidity, which may also contribute to 
an underestimation of comorbidity. During the reviewing 
of the pathology results, we did not find an indication of 
synchronous cancer in this population, and we know that 
they did not receive another gynecological cancer diagnosis 
during the study period.
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The strength of the Danish Causes of Death Register 
is its completeness, but the database contains a limitation 
in that it is the physician on call at the time of death who 
registers the cause of death, which means that it is not 
necessarily a physician who is familiar with the medical 
history. This may compromise the validity of the cause of 
death registration.
Another limitation of this study is the low number of 
patients in some strata, which could have impacted some of 
the results and explains some surprising findings, such as 
only a PS of 4 was found to impact survival, when it is well 
established that PS is a significant prognostic factor. Most 
of the patients with a missing FIGO stage had endometrial 
cancer. The majority (approximately 70%) of patients with 
endometrial cancer with a missing stage received curative 
intended treatment, indicating that they had low-stage dis-
ease, which is in line with what would be expected in an 
endometrial cancer population. This indicates that the risk of 
systematic error as a result of a missing stage is very small.
A strength of our study is that data were derived from 
valid databases of surgical and pathological data, and that 
oncologic and other relevant data were supplemented with 
data from the medical charts of the patients, including dou-
ble checking of the pathological diagnoses. As our popula-
tion derives from a database (DGCD) that collects informa-
tion on all patients diagnosed with gynecological cancer, and 
the data are collected prospectively, it greatly diminishes the 
risk of selection bias and also limits information bias from 
this database. We also adjusted for several clinically signifi-
cant covariates in our analysis in an effort to reduce potential 
confounding. Our population is, furthermore, representative 
of the entire Danish population, as described earlier.
Previous studies have shown that optimal surgical and 
medical treatment of older patients with ovarian cancer 
is feasible [37–39]—even though more toxicity is to be 
expected in this group [40, 41]. There is increasing aware-
ness on how to best manage treatment decisions in individual 
older patients with cancer and thereby provide personalized 
medicine to this complex and heterogeneous group. Extra 
focus on good supportive care is of particular importance 
in older patients with cancer. It is well known that older 
patients with cancer are under-represented in clinical trials 
and that only the fittest older patients without comorbidity 
are included [42]. This is a challenge in daily clinical prac-
tice because the majority of patients with cancer are older. 
Multidisciplinary collaboration with geriatricians in the 
oncological setting should be implemented in daily clinical 
practice because studies have indicated that a comprehen-
sive geriatric assessment is able to predict severe treatment-
related toxicity [5, 43, 44] and overall survival in different 
cancer diseases and treatment settings [45–47]. Furthermore, 
a comprehensive geriatric assessment is able to influence 
treatment choice and intensity [48–50].
5  Conclusion
Only a few studies have assessed factors influencing onco-
logic treatment decisions and survival in an older gyneco-
logical cancer population. Knowledge of how oncologic 
treatment decisions are made and the evidence behind the 
treatment of this population are sparse [51, 52]. Our study 
showed that in an older gynecological cancer population, 
age, FIGO stage, and PS, but not comorbidity, were predic-
tors of treatment decisions. Treatment choice, FIGO stage, 
and PS were predictors of mortality. Age was predictive of 
all-cause mortality in ovarian cancer, while comorbidity was 
not a predictor of mortality. Thus, our study indicates that 
age along with stage and PS might be a much stronger fac-
tor than comorbidity when making treatment decisions in 
an older cancer population. This does not, however, reduce 
the need for a pretreatment careful evaluation (e.g. geriatric 
assessment), in older patients with gynecological cancer, 
particularly those with ovarian cancer.
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